← All verdicts
Verdict

Valuation N/A

Every analyzed stock in Valuation N/A — 479 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Valuation N/A" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
MACIU
Melar Acquisition Corp. I/Cayman
Valuation N/A
Technology Risk 38 · Moderate
Price$11.25
Model IV—
P/IV—
Limited data — see page
MACIW
Melar Acquisition Corp. I/Cayman
Valuation N/A
Technology
Price$0.12
Model IV—
P/IV—
Limited data — see page
MBAVU
MBAVU
Valuation N/A
Price$10.81
Model IV—
P/IV—
Limited data — see page
MBAVW
MBAVW
Valuation N/A
Price$0.45
Model IV—
P/IV—
Limited data — see page
MBVIU
M3-Brigade Acquisition VI Corp.
Valuation N/A
Financial Services Risk 40 · Elevated
Price$10.30
Model IV—
P/IV—
Limited data — see page
MBVIW
M3-Brigade Acquisition VI Corp.
Valuation N/A
Financial Services
Price$0.35
Model IV—
P/IV—
Limited data — see page
MCAHU
Mountain Crest Acquisition 6 Corp.
Valuation N/A
Financial Services Risk 51 · Elevated
Price$10.42
Model IV—
P/IV—
Limited data — see page
MCGAU
Yorkville Acquisition Corp.
Valuation N/A
Financial Services
Price$10.34
Model IV—
P/IV—
Limited data — see page
MCGAW
Yorkville Acquisition Corp.
Valuation N/A
Financial Services
Price$0.34
Model IV—
P/IV—
Limited data — see page
MDCXW
Medicus Pharma Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.32
Model IV—
P/IV—
Limited data — see page
MESHU
Meshflow Acquisition Corp
Valuation N/A
Financial Services
Price$10.21
Model IV—
P/IV—
Limited data — see page
MESHW
Meshflow Acquisition Corp
Valuation N/A
Financial Services
Price$0.26
Model IV—
P/IV—
Limited data — see page
MEVOU
M Evo Global Acquisition Corp II
Valuation N/A
Financial Services
Price$10.19
Model IV—
P/IV—
Limited data — see page
MEVOW
M Evo Global Acquisition Corp II
Valuation N/A
Financial Services
Price$0.37
Model IV—
P/IV—
Limited data — see page
MKDWW
MKDWELL Tech Inc.
Valuation N/A
Technology Risk 43 · Elevated
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
MKLYU
McKinley Acquisition Corp
Valuation N/A
Technology
Price$10.46
Model IV—
P/IV—
Limited data — see page
MLAAU
Mountain Lake Acquisition Corp. II
Valuation N/A
Financial Services Risk 64 · High
Price$10.08
Model IV—
P/IV—
Limited data — see page
MLAAW
Mountain Lake Acquisition Corp. II
Valuation N/A
Financial Services
Price$0.21
Model IV—
P/IV—
Limited data — see page
MLACU
MLACU
Valuation N/A
Price$3.60
Model IV—
P/IV—
Limited data — see page
MMTXU
Miluna Acquisition Corp
Valuation N/A
Technology Risk 39 · Moderate
Price$10.10
Model IV—
P/IV—
Limited data — see page
MMU
WESTERN ASSET MANAGED MUNICIPALS FUND INC.
Valuation N/A
Unknown Risk 47 · Elevated
Price$9.40
Model IV—
P/IV—
Limited data — see page
MRVL
Marvell Technology, Inc.
Valuation N/A
Technology Risk 43 · Elevated
Price$236.10
Model IV—
P/IV—
Market implies +45.6%/yr vs model +16.4% · above model
NEXR
Nexera Technologies Ltd
Valuation N/A
Consumer Cyclical Risk 46 · Elevated
Price$1.55
Model IV—
P/IV—
Market implies +150.0%/yr vs model +26.8% · above model
NIVF
NewGenIvf Group Ltd
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.06
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
NOTV
Inotiv, Inc.
Valuation N/A
Industrials Risk 54 · Elevated
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
ONC
BeOne Medicines Ltd.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$346.51
Model IV—
P/IV—
Market implies +22.7%/yr vs model +46.0% · below model
ONEW
OneWater Marine Inc.
Valuation N/A
Consumer Cyclical
Price$10.73
Model IV—
P/IV—
Limited data — see page
OPRT
Oportun Financial Corp
Valuation N/A
Financial Services Risk 41 · Elevated
Price$7.87
Model IV—
P/IV—
Market implies -43.9%/yr vs model +24.9% · below model
ORCL
ORACLE CORP
Valuation N/A
Technology Risk 59 · Elevated
Price$144.79
Model IV—
P/IV—
Market implies +24.9%/yr
ORIS
ORIENTAL RISE HOLDINGS Ltd
Valuation N/A
Basic Materials Risk 49 · Elevated
Price$1.83
Model IV—
P/IV—
Market implies -50.0%/yr vs model +0.0% · below model
PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
Valuation N/A
Consumer Cyclical Risk 39 · Moderate
Price$0.22
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
PLNT
Planet Fitness, Inc.
Valuation N/A
Communication Services
Price$50.75
Model IV—
P/IV—
Limited data — see page
PSHG
Performance Shipping Inc.
Valuation N/A
Industrials Risk 38 · Moderate
Price$1.68
Model IV—
P/IV—
Market implies -39.6%/yr vs model +18.1% · below model
RFL
Rafael Holdings, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$2.28
Model IV—
P/IV—
Market implies +118.2%/yr vs model +2.0% · above model
RPAY
Repay Holdings Corp
Valuation N/A
Technology Risk 40 · Elevated
Price$3.78
Model IV—
P/IV—
Market implies +98.2%/yr vs model +9.0% · above model
RUBI
Rubico Inc.
Valuation N/A
Industrials Risk 62 · High
Price$1.46
Model IV—
P/IV—
Market implies +96.3%/yr vs model +3.0% · above model
SATS
SATS
Valuation N/A
Risk 55 · Elevated
Price$92.10
Model IV—
P/IV—
Limited data — see page
SBFM
Sunshine Biopharma Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$1.06
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
SDOT
Sadot Group Inc.
Valuation N/A
Consumer Cyclical Risk 62 · High
Price$12.39
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
SIVEF
SIVEF
Valuation N/A
Price$3.05
Model IV—
P/IV—
Limited data — see page
SNAL
Snail, Inc.
Valuation N/A
Technology
Price$2.58
Model IV—
P/IV—
Limited data — see page
STKS
ONE Group Hospitality, Inc.
Valuation N/A
Consumer Cyclical Risk 49 · Elevated
Price$1.58
Model IV—
P/IV—
Market implies -50.0%/yr vs model +30.6% · below model
SVRN
OceanPal Inc.
Valuation N/A
Industrials Risk 37 · Moderate
Price$11.95
Model IV—
P/IV—
Market implies +43.0%/yr vs model +15.0% · above model
SWBI
SMITH & WESSON BRANDS, INC.
Valuation N/A
Industrials Risk 41 · Elevated
Price$13.20
Model IV—
P/IV—
Market implies +131.3%/yr vs model -6.4% · above model
TOPS
TOP SHIPS INC.
Valuation N/A
Industrials Risk 55 · Elevated
Price$0.72
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.4% · below model
TRVI
Trevi Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$15.90
Model IV—
P/IV—
Limited data — see page
TSAT
Telesat Corp
Valuation N/A
Communication Services
Price$49.75
Model IV—
P/IV—
Limited data — see page
TSI
TSI
Valuation N/A
Price$4.34
Model IV—
P/IV—
Limited data — see page
TSM
TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD
Valuation N/A
Technology Risk 38 · Moderate
Price$418.01
Model IV—
P/IV—
Market implies +27.1%/yr
TTRX
Turn Therapeutics Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$12.69
Model IV—
P/IV—
Limited data — see page
TU
TELUS CORP
Valuation N/A
Communication Services Risk 54 · Elevated
Price$9.16
Model IV—
P/IV—
Limited data — see page
TURB
Turbo Energy, S.A.
Valuation N/A
Technology Risk 32 · Moderate
Price$1.15
Model IV—
P/IV—
Limited data — see page
TV
GRUPO TELEVISA, S.A.B.
Valuation N/A
Communication Services
Price$2.38
Model IV—
P/IV—
Limited data — see page
TVA
Texas Ventures Acquisition III Corp
Valuation N/A
Financial Services
Price$10.55
Model IV—
P/IV—
Limited data — see page
TVACU
Texas Ventures Acquisition III Corp
Valuation N/A
Financial Services
Price$10.77
Model IV—
P/IV—
Limited data — see page
TVACW
Texas Ventures Acquisition III Corp
Valuation N/A
Financial Services
Price$0.26
Model IV—
P/IV—
Limited data — see page
TVAI
Thayer Ventures Acquisition Corp II
Valuation N/A
Financial Services
Price$10.40
Model IV—
P/IV—
Limited data — see page
TVAIR
Thayer Ventures Acquisition Corp II
Valuation N/A
Financial Services
Price$0.14
Model IV—
P/IV—
Limited data — see page
TVGN
Tevogen Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$7.36
Model IV—
P/IV—
Limited data — see page
TWLV
Twelve Seas Investment Co III/Cayman
Valuation N/A
Financial Services
Price$10.07
Model IV—
P/IV—
Limited data — see page